Hemogenyx Pharmaceuticals Plc

LSE HEMO.L

Hemogenyx Pharmaceuticals Plc Return on Assets (ROA) for the year ending December 31, 2023

Hemogenyx Pharmaceuticals Plc Return on Assets (ROA) is NA for the year ending December 31, 2023. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Hemogenyx Pharmaceuticals Plc Return on Assets (ROA) for the year ending December 31, 2022 was -61.31%.
Hemogenyx Pharmaceuticals Plc Return on Assets (ROA) for the year ending December 31, 2020 was -79.39%, a 42.64% change year over year.
Hemogenyx Pharmaceuticals Plc Return on Assets (ROA) for the year ending December 31, 2019 was -138.41%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

LSE: HEMO.L

Hemogenyx Pharmaceuticals Plc

CEO	Dr. Vladislav Sandler Ph.D.
IPO Date	Nov. 9, 2015
Location	United Kingdom
Headquarters	60 Gracechurch Street
Employees	17
Sector	Healthcare
Industries Biotechnology

Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years